title: Effectiveness of casein phosphopeptide-amorphous calcium phosphate and lysozyme, lactoferrin, and lactoperoxidase in reducing Streptococcus mutans counts in dentinal caries.
abstract: This study compared the capacity of casein phosphopeptide-amorphous calcium phosphate (CPP-ACP) to that of a combination of lysozyme, lactoferrin, and lactoperoxidase (LLL) in root canal disinfectant for reducing the Streptococcus mutans counts from dentinal caries. Forty human permanent third molars were selected, and flat dentin surfaces were created. Carious lesions were induced using a microbiological model. The specimens were randomly divided into 2 groups (n = 20) according to the type of agent used: group 1, CPP-ACP; group 2, LLL. The S mutans counts were performed before application and after the first, second, and third applications of the agents. The duration of each application was 3 minutes. Carious dentin specimens were homogenized, diluted, and seeded onto mitis salivarius-bacitracin plates for viable counts of S mutans. Results showed that there was no significant reduction in the number of S mutans in group 1 after the applications of CPP-ACP (P > 0.05). In group 2, a significant reduction of S mutans was observed after the third application of LLL (P < 0.01). These results indicate that 3 applications of LLL enzymes can be used to reduce the number of S mutans in dentinal caries lesions.
authors.forename: Sérgio Luiz
authors.initials: SL
authors.lastname: Pinheiro
authors.forename: Giuliana Rodrigues
authors.initials: GR
authors.lastname: Azenha
authors.forename: Giovana Spagnolo Albamonte
authors.initials: GS
authors.lastname: Araujo
authors.forename: Regina Maria
authors.initials: RM
authors.lastname: Puppin Rontani
mesh_terms: D058491:Bacterial Load / Q000187:drug effects; D002364:Caseins / Q000494:pharmacology / Q000627:therapeutic use*; D003731:Dental Caries / Q000188:drug therapy / Q000382:microbiology*; D004359:Drug Therapy, Combination; D006801:Humans; D007781:Lactoferrin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D007784:Lactoperoxidase / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D009113:Muramidase / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D013295:Streptococcus mutans / Q000187:drug effects*
chemical_list: D002364:Caseins; C447032:casein phosphopeptide-amorphous calcium phosphate nanocomplex; D007784:Lactoperoxidase; D009113:Muramidase; D007781:Lactoferrin